Galectin Therapeutics Q3 2024 GAAP EPS $(0.18) Misses $(0.12) Estimate
Benzinga Newsdesk 1 year ago
EarningsEarnings MissesNews
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.12) by 50 percent. This is a 25 percent increase over losses of $(0.24) per share from
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.12) by 50 percent. This is a 25 percent increase over losses of $(0.24) per share from the same period last year.